Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Completed · Phase 2

Conditions studied: Renal Impairment

In brief

The purpose of this trial was to evaluate whether the study drug, LIK066, causes glucose excretion in urine in patients with varying degrees of decreased kidney function and in subjects with normal kidney function. Blood samples were collected to measure the concentrations of LIK066 and to study the pharmacokinetics of LIK066. Pharmacokinetics is meant to study how LIK066 is absorbed, distributed and eliminated, in other words what the body does to the drug. The results of this study may be used to help determine whether LIK066 can be used to treat people with reduced kidney function and the proper dosing regimen.

Key facts

Study ID
NCT03131479
Run by
Novartis Pharmaceuticals
People needed
53
Starts
2017-04-28
Expected to finish
2018-01-16
Last updated by the study team
2021-01-05

Who can join

Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.